乌干达妊娠期疟疾间歇预防治疗中复发性恶性疟原虫血症与耐药突变
在乌干达布西亚比较每月磺胺多辛-乙胺嘧啶(SP)、双氢青蒿素-哌喹(DP)及DP+SP用于妊娠期间歇预防治疗(IPTp)的试验中,对1377份样本测序发现SP组28天复发性疟原虫血症累积风险57.8%,显著高于DP组4.1%和DP+SP组3.9%。SP组还显著增加症状性疟疾和再燃风险,并选择耐药突变增加。
要点
- SP组28天复发性疟原虫血症累积风险57.8%,DP组4.1%,DP+SP组3.9%。
- SP组症状性疟疾风险9.3%,再燃风险40.1%,均显著高于DP方案。
- IPTp-SP后PfDHFR I164L与PfDHPS A581G合并流行率从24.9%升至35.2%。
核心结论
- 每月IPTp-SP抗疟预防效果差,并选择耐药突变增加,提示该干预价值存疑。
研究设计与样本
- 在乌干达布西亚比较每月SP、DP和DP+SP用于IPTp的试验中,对1377份样本测序,并评估28天复发性疟原虫血症累积风险。
主要发现
- SP组28天复发性疟原虫血症累积风险57.8%,DP组4.1%,DP+SP组3.9%。
- SP组症状性疟疾累积风险9.3%,DP组1.1%,DP+SP组0.3%。
- SP组再燃性疟原虫血症累积风险40.1%,DP组2.0%,DP+SP组0.8%,初产妇风险最高。
- IPTp启动日771份样本中,PfDHFR和PfDHPS五个耐药突变流行率近100%,I164L与A581G合并流行率26.5%。
- IPT-SP组I164L与A581G合并流行率从启动时24.9%显著升至接受IPTp-SP后35.2%。
关键数值与推荐
- SP组28天复发性疟原虫血症累积风险57.8%、症状性疟疾9.3%、再燃40.1%,均显著高于DP和DP+SP组。
- IPTp启动日五个耐药突变流行率近100%,I164L与A581G合并流行率26.5%。
- IPT-SP组I164L与A581G合并流行率从24.9%升至35.2%。
临床怎么用
- 在SP耐药高流行区,IPTp-SP的预防效果差且可能选择耐药,临床应考虑替代方案。
局限性
- 突变感染与再燃风险增加关联未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is important. METHODS: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP + SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. RESULTS: Among 771 samples collected on the day IPTp was initiated, the prevalences of 5 resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP + SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP + SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP + SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. CONCLUSIONS: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine had poor antimalarial preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.
引用
- Kizza J, Katairo T, Kakuru A, et al. Recurrent Plasmodium falciparum Parasitemia and Drug Resistance Mutations During Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda. J Infect Dis. 2026. PMID: 41679334. doi:10.1093/infdis/jiag074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。